bluebird bio (BLUE) Projected to Post Quarterly Earnings on Monday

bluebird bio (NASDAQ:BLUE) is projected to announce its earnings results on Monday, March 24th. Analysts expect the company to announce earnings of ($6.30) per share and revenue of $27.07 million for the quarter.

bluebird bio Stock Performance

Shares of NASDAQ BLUE opened at $3.90 on Friday. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio has a 52-week low of $3.56 and a 52-week high of $28.60. The stock has a market capitalization of $37.92 million, a price-to-earnings ratio of -0.10 and a beta of 0.76. The stock’s fifty day simple moving average is $5.97 and its 200 day simple moving average is $8.00.

Analysts Set New Price Targets

Several brokerages have commented on BLUE. Baird R W cut shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Barclays boosted their price target on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. StockNews.com started coverage on shares of bluebird bio in a research report on Thursday. They set a “sell” rating on the stock. Finally, Wells Fargo & Company lowered their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, bluebird bio currently has a consensus rating of “Hold” and a consensus target price of $51.00.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.